Yuhan Corporation FY 2025 Annual ReportBeta
Yuhan Corporation annual report for FY 2025, filed with DART (Korea Financial Supervisory Service) on March 12, 2026. This page provides AI-powered English analysis including business overview, management discussion & analysis (MD&A), risk factors, and KIFRS consolidated financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE).
Yuhan Corporation FY 2025 Annual Report Analysis
Business Overview
- • Pharmaceutical business sales KRW 1.40T in FY2025, +3.5% driven by innovation drug Lekraza and new improved drugs lineup
- • Lekraza EGFR-targeted NSCLC drug global commercialization with multi-region approvals: US FDA Aug 2024, EU EC Jan 2025, Japan PMDA Mar 2025, China NMPA Jul 2025
Management Discussion & Analysis
- • Revenue KRW 2.19T (+5.7% YoY), operating profit KRW 104.4B (+90.2%), net income KRW 185.3B (+235.9%) in FY2025
- • Overseas business revenue grew 26.1% YoY to KRW 386.6B led by increased exports of AIDS and Hepatitis C raw materials
Risk Factors
- • KRW 7.65B pre-tax income sensitivity to 10% KRW FX rate increase at FY2025 end, up from KRW 6.72B in prior year
- • Largest equity investment price risk KRW 62.78B market value, with ±KRW 4.83B post-tax equity impact at FY2025 end
Yuhan Corporation FY 2025 Key Financial MetricsDART
Total Assets
KRW 3.22T
▲ +9.5% YoY
Operating Cash Flow
KRW 106.2B
▲ +94.6% YoY
CapEx
KRW 99.6B
▼ -14.9% YoY
Source: KIFRS consolidated financial data from Yuhan Corporation annual report on DART. All figures in KRW.
Source: DART (Korea Financial Supervisory Service) · AI summaries generated from the original Korean filing (English output) · Beta: coverage is expanding